(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer

Pancreatic Cancer Clinical Trial

— PM-01  

Official title:

PM-01: Phase 1b Study of PGG Beta Glucan (Imprime PGG®) in Combination With Anti-MUC1 Antibody (BTH1704) and Gemcitabine (Gemzar®) for the Treatment of Advanced Pancreatic Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02132403
• Other study ID #: 2013-1115
• Status: Terminated
• Phase: Phase 1
• First received: May 5, 2014
• Last updated: April 29, 2015
• Start date: August 2014
• Est. completion date: April 2015

Study information

• Verified date: April 2015
• Source: University of Illinois at Chicago
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: UIC Cancer Center Data and Safety Monitoring Committee
• Study type: Interventional

Clinical Trial Summary

This Phase Ib dose escalation study will evaluate BTH1704, a monoclonal antibody that targets an aberrantly glycosylated antigen Mucin 1, and Imprime PGG, a glucan contained in yeast that is essential in triggering a leukocyte-mediated cytotoxic response towards tumor cells, in combination with gemcitabine in patients with advanced PDAC. The three intravenous drugs are taken in tandem 4 times in a 28-day cycle. The MAD of BTH1704 (BTH, 3 dose levels) in combination with gemcitabine (Gem) and Imprime PGG (I) will be determined using a standard "3+3" design. Treatment continues until disease progression, unacceptable toxicity, physician discretion, or patient refusal.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: April 2015
• Est. primary completion date: April 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female = 18 years

2. Histologically or cytologically confirmed adenocarcinoma of the pancreas, including pancreatic adenosquamous carcinoma, pancreatic anaplastic adenocarcinoma, pancreatic signet ring carcinoma, papillary mucinous carcinoma, acinar cell carcinoma, and ampulla of vater carcinoma,that is locally advanced (not able to proceed with surgery), recurrent, or metastatic (mixed adenocarcinoma of the pancreas is acceptable where the invasive component is predominantly adenocarcinoma)

3. Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1

4. Has an ECOG PS of 0, 1, or 2

5. Has been off chemotherapy for > or = 2 weeks

6. Has a patent biliary stent if required for biliary ductal obstruction, has adequate nutritional intake, and pain which is stable for a minimum of 24 hrs (pain score = 3/10)

7. Has total bilirubin < 2 mg/dL, AST and ALT < 3.0 × ULN or < 5 x ULN for subjects with known hepatic metastases

8. Has serum creatinine < 2.5 × ULN

9. Has hemoglobin = 9 g/dL, ANC = 1.0 × 10^9/L, and platelet count = 100 × 10^9/L

10. Must be willing and able to comply with study

11. Has read, understood and signed the ICF

12. Women of childbearing potential must not be pregnant or breast-feeding. In addition, a medically acceptable method of birth control must be used or total abstinence. Women who are postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) are not considered to be WOCP.

13. Men who are not surgically or medically sterile must agree to use an acceptable method of contraception. Male patients with female sexual partners who are pregnant, possibly pregnant, or who could become pregnant during the study must agree to use condoms at least 30 days after the last dose of study drug. Total abstinence is an acceptable alternative.

14. Prior systemic treatments for metastatic disease are permitted, including targeted therapies, biologic response modifiers, chemotherapy, hormonal therapy, or investigational therapy.

15. Availability of tissue if applicable (from the primary tumor or metastases)for banking

16. Willingness to donate blood for biomarker studies

17. Must have received at least one prior systemic chemotherapy on which disease progressed

Exclusion Criteria:

1. Has a diagnosis of resectable pancreatic adenocarcinoma

2. Had surgery within 4 weeks prior to study treatment

3. Has either untreated or symptomatic CNS mets

4. Has a known hypersensitivity to BTH1704, murine proteins, or any component of BTH1704

5. Has a known hypersensitivity to baker's yeast

6. Has had previous exposure to Imprime PGG

7. Has previously received an organ or progenitor/stem cell transplant

8. Has a history of blood clots, pulmonary embolism, or DVT unless controlled by anticoagulant treatment

9. Has a known history of HIV positivity or untreated & uncontrolled hepatitis B or C

10. Has any clinically significant infection

11. Has any other severe, uncontrolled medical condition, including uncontrolled DM or unstable CHF or has a known or suspected allergy to the study drug

12. Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormality that may increase the risk associated with study participation

13. Presence of any non-healing wound, fracture, or ulcer

14. Has any condition that, in the opinion of the investigator, might jeopardize the safety of the patient or interfere with protocol compliance

15. Has any mental or medical condition that prevents the patient from giving informed consent

16. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to gemcitabine or drugs to formulate.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• BTH1704
BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
• IMPRIME PGG
Imprime PGG at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
• Gemcitabine
Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day (4 week) cycle.

Locations

Country	Name	City	State
United States	UI Cancer Center	Chicago	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
University of Illinois at Chicago	Biothera

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose (MTD)	The primary objective of this Phase 1b study is to determine the maximal administered dose (MAD) of BTH1704 (Mucin-1 targeted antibody) in combination with gemcitabine and Imprime PGG (beta 1,3/1,6 glucan) when given to patients with advanced and previously treated pancreatic ductal adenocarcinoma (PDAC).	Up to 30 days post last dose	Yes
Secondary	Adverse Effects	Characterize adverse effects (AE) of I-BTH-Gem in patients with advanced PDAC in the second and third line setting.	Up to 30 days post final dose	Yes
Secondary	Disease Response based on RECIST Criteria	Evaluate clinical response of I-BTH-Gem in patients with advanced PDAC in the second and third line setting (RECIST v 1.1).	Up to 8 weeks following final dose.	No